Follicular Lymphoma
📧 Sign up to get email alerts when something new happens for Follicular Lymphoma.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS trial_result · 2023-08-04Clinical Trial Update: Study of Tazemetostat as Single Agent in Solid Tumors or B-cell Lymphomas and in Combination With Prednisolone in DLBCL [Phase 1, Phase 2]
Clinical trial update for tazemetostat as a single agent and in combination in B-cell lymphomas and solid tumors completed with results post…
-
CLINICAL_TRIALS trial_result · 2023-07-25Clinical Trial Update: Autologous Cells Derived Anti-CD19 CAR-Engineered T Cells With Concurrent BTK Inhibitor for B Cell Lymphoma [Phase 3]
Phase 3 trial investigating autologous anti-CD19 CAR-T cells given with a BTK inhibitor for B cell lymphomas, with an unspecified status.
-
CLINICAL_TRIALS trial_result · 2023-07-24Clinical Trial Update: Study to Assess Umbralisib Plus Ublituximab in Participants With Treatment Naïve Follicular Lymphoma [Phase 2]
Phase 2 trial of umbralisib plus ublituximab in treatment-naïve follicular lymphoma was terminated; results posted in 2023.
-
CLINICAL_TRIALS trial_result · 2023-07-20Clinical Trial Update: Gene Therapy in Treating Patients With Human Immunodeficiency Virus-Related Lymphoma Receiving Stem Cell Transplant [Phase 1, Phase 2]
This update reports results from a Phase 1/2 clinical trial of a gene therapy for HIV-related lymphomas in patients undergoing stem cell tra…
-
CLINICAL_TRIALS trial_result · 2023-07-18Clinical Trial Update: Rituximab With or Without Yttrium Y-90 Ibritumomab Tiuxetan in Treating Patients With Untreated Follicular Lymphoma [Phase 3]
A phase 3 trial evaluating rituximab with or without Y-90 ibritumomab tiuxetan in untreated follicular lymphoma was terminated; results have…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
FDA approval · 2023-06-15FDA Approved: COLUMVI — Original Application (Genentech, Inc.)
FDA approved Columvi (glofitamab) from Genentech via an original biologics license application. The approval covers use in adults with relap…
-
CLINICAL_TRIALS trial_result · 2023-06-09Clinical Trial Update: High Dose Cyclophosphamide, Tacrolimus, and Mycophenolate Mofetil in Preventing Graft Versus Host Disease in Patients With Hematological Malignancies Undergoing Myeloablative or Reduced Intensity Donor Stem Cell Transplant [Phase 2]
Phase 2 clinical trial evaluating high-dose cyclophosphamide, tacrolimus, and mycophenolate mofetil to prevent graft-versus-host disease in …
-
FDA approval · 2023-06-05FDA Approved: BENDAMUSTINE — Original Application (Meitheal Pharmaceuticals Inc.)
The FDA approved the original application for Bendamustine HCl from Meitheal Pharmaceuticals Inc., sanctioning a generic version of bendamus…
-
CLINICAL_TRIALS trial_result · 2023-03-31Clinical Trial Update: First Line Therapy of Advanced Stage Follicular Lymphoma in Patients < 60 Years Not Eligible fo Standard Immunochemotherapy and in All Patients ≥ 60 Years [Phase 2]
Phase 2 trial update on first-line therapy for advanced Follicular Lymphoma in patients under 60 not eligible for standard immunochemotherap…
-
FDA approval · 2023-03-24FDA Approved: LENALIDOMIDE — Supplemental Application (Apotex Corp.)
FDA approved Apotex Corp.'s supplemental application for lenalidomide (ANDA211022), authorizing the marketing of a generic lenalidomide prod…
-
FDA approval · 2023-03-24FDA Approved: LENALIDOMIDE — Supplemental Application (Sun Pharmaceutical Industries, Inc.)
The FDA approved a supplemental application for lenalidomide submitted by Sun Pharmaceutical Industries, Inc.
-
FDA approval · 2023-03-24FDA Approved: LENALIDOMIDE — Supplemental Application (Aurobindo Pharma Limited)
The FDA approved a supplemental application for Lenalidomide submitted by Aurobindo Pharma Limited to support the continued availability of …
-
CLINICAL_TRIALS trial_result · 2023-03-21Clinical Trial Update: Pembrolizumab Alone or With Idelalisib or Ibrutinib in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia or Other Low-Grade B-Cell Non-Hodgkin Lymphomas [Phase 2]
Phase 2 trial of pembrolizumab alone or with idelalisib or ibrutinib in relapsed/refractory chronic lymphocytic leukemia or various low-grad…
-
CLINICAL_TRIALS trial_result · 2023-03-17Clinical Trial Update: Study of OBINUTUZUMAB Combined to LENALIDOMIDE for the Treatment of Relapsed/Refractory Follicular and Aggressive B-cell Lymphoma [Phase 1, Phase 2]
Clinical trial updates the combination of obinutuzumab with lenalidomide for relapsed/refractory follicular and aggressive B-cell lymphomas,…
-
CLINICAL_TRIALS trial_result · 2023-03-16Clinical Trial Update: TC-110 T Cells in Adults With Relapsed or Refractory Non-Hodgkin Lymphoma or Acute Lymphoblastic Leukemia [Phase 1, Phase 2]
Phase 1/2 trial update for TC-110 T cells in adults with relapsed or refractory non-Hodgkin lymphoma or acute lymphoblastic leukemia (comple…
-
FDA approval · 2023-03-06FDA Approved: LENALIDOMIDE — Original Application (Sun Pharmaceutical Industries, Inc.)
FDA approved Sun Pharmaceutical Industries' generic lenalidomide (LENALIDOMIDE) under ANDA211846.
-
FDA approval · 2023-03-06FDA Approved: LENALIDOMIDE — Original Application (Mylan Pharmaceuticals Inc.)
FDA approved Lenalidomide from Mylan Pharmaceuticals as an original application (ANDA), marking the approval of a generic lenalidomide.
-
FDA approval · 2023-03-06FDA Approved: LENALIDOMIDE — Original Application (Aurobindo Pharma Limited)
FDA approved Lenalidomide as a generic product under an original application from Aurobindo Pharma Limited.
-
FDA approval · 2023-03-06FDA Approved: LENALIDOMIDE — Original Application (Teva Pharmaceuticals, Inc.)
FDA approved a generic lenalidomide product for Teva under ANDA201452, expanding access to lenalidomide formulations.
-
FDA approval · 2023-03-06FDA Approved: LENALIDOMIDE — Original Application (Alvogen, Inc.)
FDA approved Alvogen, Inc.'s original Abbreviated New Drug Application for a generic lenalidomide product (ANDA 210480).
-
FDA approval · 2023-03-06FDA Approved: LENALIDOMIDE — Original Application (EXELAN PHARMACEUTICALS INC.)
FDA approves a generic lenalidomide product from Exelan Pharmaceuticals under an original application. The drug is indicated for several hem…
-
CLINICAL_TRIALS trial_result · 2023-02-16Clinical Trial Update: Umbilical Cord Blood NK Cells, Rituximab, High-Dose Chemotherapy, and Stem Cell Transplant in Treating Patients With Recurrent or Refractory B-Cell Non-Hodgkin's Lymphoma [Phase 2]
Phase 2 trial evaluating Umbilical Cord Blood NK cells with Rituximab, high-dose chemotherapy, and stem cell transplant in recurrent or refr…
-
CLINICAL_TRIALS trial_result · 2023-02-09Clinical Trial Update: Vincristine Sulfate Liposome Injection (Marqibo®), Bendamustine and Rituximab-Phase I Trial in Indolent B-cell Lymphoma [Phase 1]
Phase I trial evaluating a combination of Vincristine Sulfate Liposome Injection with Bendamustine and Rituximab in indolent B-cell lymphoma…
-
FDA approval · 2023-02-08FDA Approved: LENALIDOMIDE — Original Application (Sun Pharmaceutical Industries, Inc.)
FDA approves Sun Pharmaceutical Industries' Lenalidomide Original Application, granting a generic lenalidomide product for multiple myeloma …
-
CLINICAL_TRIALS trial_result · 2023-01-20Clinical Trial Update: Ibrutinib in Treating Patients With Refractory or Relapsed Lymphoma After Donor Stem Cell Transplant [Phase 2]
Phase 2 trial evaluating ibrutinib in patients with refractory or relapsed lymphoma after donor stem cell transplant completed; results post…